middle.news
Clarity Boosts US Production Capacity for Prostate Cancer Imaging Agent
8:42am on Tuesday 14th of April, 2026 AEST
•
Healthcare
Read Story
Clarity Boosts US Production Capacity for Prostate Cancer Imaging Agent
8:42am on Tuesday 14th of April, 2026 AEST
Key Points
Commercial Manufacturing Agreement signed with Nucleus RadioPharma
Capacity to produce up to 600,000 doses annually across two US sites
Agreement supports planned launch pending Phase III trial completion and FDA approval
Builds on existing supply deals with SpectronRx, Theragenics, and Nusano
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clarity Pharmaceuticals (ASX:CU6)
OPEN ARTICLE